Profound Medical (PROF)

TULSA-PRO is used for physician-defined ablation of malignant or benign prostate tissue, including whole-gland or more focal treatment approaches. Its transurethral ultrasound applicator delivers energy from within the urethra, while closed-loop software adjusts treatment based on temperature data. This combination differentiates Profound from more conventional prostate interventions that rely on surgery, radiation or less integrated forms of thermal ablation.

The company’s business model includes the sale or placement of capital equipment, along with recurring revenue from single-use devices, procedure-related accessories and services. That structure gives Profound exposure both to hospital and imaging-center adoption of its platform and to ongoing patient procedure volume.

Profound also applies its core expertise in MRI-guided thermal therapy beyond the prostate through related technologies for soft-tissue ablation. As a medical device company, its growth depends on physician training, clinical evidence, reimbursement, regulatory compliance and the willingness of healthcare providers to invest in new treatment infrastructure. For investors, Profound Medical represents a specialized medtech business positioned at the intersection of urology, interventional radiology, robotics and precision thermal therapy.